garenoxacin has been researched along with Chlamydia pneumoniae Infections in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hosono, H; Ishida, T; Izumikawa, K; Kohno, S; Kushimoto, S; Miyashita, N; Watanabe, A | 1 |
Hammerschlag, MR; Reznik, T; Roblin, PM | 1 |
2 other study(ies) available for garenoxacin and Chlamydia pneumoniae Infections
Article | Year |
---|---|
Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan.
Topics: Adult; Anti-Bacterial Agents; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Tablets | 2014 |
In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
Topics: Adult; Anti-Infective Agents; Canada; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Fluoroquinolones; Humans; Indoles; Japan; Microbial Sensitivity Tests; Pneumonia, Bacterial; Quinolones; United States | 2003 |